Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) Invested Capital (2020 - 2025)

Bioventus (BVS) has disclosed Invested Capital for 6 consecutive years, with $228.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 30.33% year-over-year to $228.4 million, compared with a TTM value of $228.4 million through Dec 2025, up 30.33%, and an annual FY2025 reading of $228.4 million, up 30.33% over the prior year.
  • Invested Capital was $228.4 million for Q4 2025 at Bioventus, up from $177.3 million in the prior quarter.
  • Across five years, Invested Capital topped out at $965.3 million in Q4 2021 and bottomed at $175.3 million in Q4 2024.
  • Average Invested Capital over 5 years is $342.4 million, with a median of $231.9 million recorded in 2021.
  • The sharpest move saw Invested Capital surged 506.52% in 2021, then tumbled 73.37% in 2023.
  • Year by year, Invested Capital stood at $965.3 million in 2021, then decreased by 13.99% to $830.3 million in 2022, then crashed by 73.37% to $221.1 million in 2023, then fell by 20.73% to $175.3 million in 2024, then surged by 30.33% to $228.4 million in 2025.
  • Business Quant data shows Invested Capital for BVS at $228.4 million in Q4 2025, $177.3 million in Q3 2025, and $201.3 million in Q2 2025.